PMC:7074432 / 1780-2391 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"96","span":{"begin":0,"end":13},"obj":"Gene"},{"id":"97","span":{"begin":97,"end":105},"obj":"Species"},{"id":"98","span":{"begin":154,"end":162},"obj":"Species"},{"id":"99","span":{"begin":196,"end":204},"obj":"Species"},{"id":"100","span":{"begin":218,"end":233},"obj":"Species"},{"id":"101","span":{"begin":354,"end":362},"obj":"Species"},{"id":"102","span":{"begin":423,"end":431},"obj":"Species"},{"id":"103","span":{"begin":484,"end":493},"obj":"Species"},{"id":"104","span":{"begin":60,"end":69},"obj":"Species"},{"id":"105","span":{"begin":172,"end":183},"obj":"Chemical"},{"id":"106","span":{"begin":266,"end":277},"obj":"Chemical"},{"id":"107","span":{"begin":314,"end":325},"obj":"Chemical"},{"id":"108","span":{"begin":408,"end":419},"obj":"Chemical"},{"id":"109","span":{"begin":437,"end":448},"obj":"Chemical"}],"attributes":[{"id":"A96","pred":"tao:has_database_id","subj":"96","obj":"Gene:4758"},{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"Tax:1335626"},{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"Tax:9606"},{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"Tax:9606"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"Tax:11309"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"Tax:1335626"},{"id":"A102","pred":"tao:has_database_id","subj":"102","obj":"Tax:1335626"},{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"Tax:2697049"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"Tax:11309"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"MESH:D053139"},{"id":"A106","pred":"tao:has_database_id","subj":"106","obj":"MESH:D053139"},{"id":"A107","pred":"tao:has_database_id","subj":"107","obj":"MESH:D053139"},{"id":"A108","pred":"tao:has_database_id","subj":"108","obj":"MESH:D053139"},{"id":"A109","pred":"tao:has_database_id","subj":"109","obj":"MESH:D053139"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T107","span":{"begin":14,"end":24},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T106","span":{"begin":97,"end":105},"obj":"SP_9"},{"id":"T105","span":{"begin":172,"end":183},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T104","span":{"begin":218,"end":227},"obj":"NCBITaxon:7719"},{"id":"T103","span":{"begin":228,"end":233},"obj":"NCBITaxon:10239"},{"id":"T102","span":{"begin":266,"end":277},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T101","span":{"begin":314,"end":325},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T100","span":{"begin":354,"end":362},"obj":"SP_9"},{"id":"T99","span":{"begin":408,"end":419},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T98","span":{"begin":423,"end":431},"obj":"SP_9"},{"id":"T97","span":{"begin":437,"end":448},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T96","span":{"begin":484,"end":493},"obj":"SP_7"}],"text":"Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":60,"end":69},"obj":"Disease"},{"id":"T14","span":{"begin":218,"end":227},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T8","span":{"begin":77,"end":78},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T9","span":{"begin":140,"end":141},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":151,"end":153},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T11","span":{"begin":228,"end":233},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T12","span":{"begin":244,"end":246},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T13","span":{"begin":433,"end":435},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":"Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T16","span":{"begin":0,"end":24},"obj":"Chemical"},{"id":"T17","span":{"begin":14,"end":24},"obj":"Chemical"},{"id":"T18","span":{"begin":172,"end":183},"obj":"Chemical"},{"id":"T19","span":{"begin":266,"end":277},"obj":"Chemical"},{"id":"T20","span":{"begin":314,"end":325},"obj":"Chemical"},{"id":"T21","span":{"begin":408,"end":419},"obj":"Chemical"},{"id":"T22","span":{"begin":437,"end":448},"obj":"Chemical"},{"id":"T23","span":{"begin":586,"end":591},"obj":"Chemical"}],"attributes":[{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_52425"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]"}

{"project":"LitCovid-sentences","denotations":[{"id":"T15","span":{"begin":0,"end":192},"obj":"Sentence"},{"id":"T16","span":{"begin":193,"end":611},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]"}

{"project":"2_test","denotations":[{"id":"32201439-30012113-47219407","span":{"begin":370,"end":372},"obj":"30012113"},{"id":"32201439-30882305-47219408","span":{"begin":433,"end":435},"obj":"30882305"},{"id":"32201439-31986264-47219409","span":{"begin":608,"end":610},"obj":"31986264"},{"id":"T19064","span":{"begin":370,"end":372},"obj":"30012113"},{"id":"T33497","span":{"begin":433,"end":435},"obj":"30882305"},{"id":"T42850","span":{"begin":608,"end":610},"obj":"31986264"}],"text":"Neuraminidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]"}